side effects include:
residual sedation
drowsiness
lethargy
vertigo
nausea
vomiting
headache

reported side effect
somnolence
somnolencepostmarketing reports
sedation
residual sedation
hangover
effect
drowsiness
lethargy
vertigo
localized/diffuse neuralgic pain
headache
hyperactivity
hypotension
hyperkinesia
ataxia
central nervous system
cns
depression
dizziness
impairment of fine motor skills
grand
mal convulsion
prolonged coma
depressed/absent reflexes
nystagmus
drowsiness/sedation
continued use
diffuse neuralgic pain
psychoneurotic patients with insomnia
pain
neck
shoulders
upper limbs
paroxysms
morning
patients
pain
days after discontinuation of this drug
hyperactivity
geriatric patients
postmarketing reports
accentuated
emotional disturbances/phobias
aggression
excitement/hyperexcitability
restlessness
delirium
irritability
agitation
confusion
nightmares
nervousness
psychiatric disturbance
hallucinations
insomnia/sleep disturbance
anxiety
abnormality in thinking
paradoxical reaction
unusual excitement
mental depression/depression
cognitive impairment
behavioral disturbances in children
abnormal behavior
mood
subtle mood changes
related mood disorder
suicidal ideation
memory/concentration/judgment impairment
withdrawal syndrome
tolerance
dependence
psychic/physical dependence
mental confusion/confusion
disorientation
patients
experienced paradoxical excitement
restlessness
delirium in the presence of pain
paradoxical reactions
hallucinations
restlessness
hyperexcitability
confusion
pediatric patients
pediatric patients
aggression
irritability
postmarketing reports
antiepileptic hypersensitivity syndrome
fever
rash
lymphadenopathy
lymphocytosis
eosinophilia
hematological abnormalities
other organ involvement
antiepileptic hypersensitivity syndrome
weeks after first exposure
day of rechallenge
syndrome
cross reactivity with other antiepileptic agents
skin eruptions
fever
delirium
marked changes in the liver
other organs
postmarketing reports
erythematous dermatitis
exfoliative dermatitis
stevens-johnson syndrome
toxic epidermal necrolysis
skin eruptions
maculopapular/morbilliform/scarlatiniform rashes
dermatitis
erythema multiforme
drug eruption
evidence of connective tissue changes
skin blisters/bullae
photosensitivity
erythroderma
urticaria
postmarketing reports
localized/diffuse
arthritic pain
osteomalacia
rickets
bone mineral density
risk of fracture
dupuytren
contracture
bone metabolism disorder
frozen shoulder
ledderhose
syndrome
general joint pain
osteopenia
osteoporosis
fractures
arthritic pain
psychoneurotic patients with insomnia
pain
neck
shoulders
upper limbs
paroxysms
morning
patients
pain
days after discontinuation of therapy
decreased bone mineral density
dupuytren
contracture
osteopenia
osteoporosis
fractures
patients
receiving long-term therapy
exact mechanism of action in bones
postmarketing reports
inebriation
drunk-like effect
fever
neonatal sedation
neonatal drug dependence/withdrawal
neonatal symptoms
resembling vitamin k deficiency
neonatal bleeding
vitamin k deficiency
cleft lip
palate
body temperature
postmarketing reports
megaloblastic anemia
macrocytic anemia
aplastic anemia
agranulocytosis
thrombocytopenia
hypoprothrombinemia
methemoglobinemia
purpura
lymphocytosis
megaloblastic anemia
chronic use of this drug
deficiency
methemoglobinemia
infants
mothers
drug
postmarketing reports
circulatory collapse
peripheral vascular collapse
weak heartbeat
circulatory failure
bradycardia
hypotension
profound shock
vasodilation
postmarketing reports
respiratory depression
severe/significant respiratory depression
apnea
hypoventilation
bronchospasm
laryngospasm
bronchospasm
laryngospasm
patients
formulation
postmarketing reports
abnormal hepatic function
hepatitis
liver damage
cholestasis
toxic hepatitis
jaundice
postmarketing reports
hypocalcemia
folate deficiency
abnormal vitamin d metabolism
vitamin d requirements
resulting from abnormal vitamin d metabolism
vitamin k deficiency
hypophosphatemia
postmarketing reports
nausea
vomiting
constipation
diarrhea
hypersensitivity reactions
acquired hypersensitivity
patients with a higher risk
developing reactions
asthma
urticaria
angioedema
postmarketing reports
localized swelling
eyelids
cheeks
lips
hypersensitivity reactions
angioedema
skin rashes
exfoliative dermatitis
angioedema
postmarketing reports
injection site reactions
local necrosis after extravasation
iv/subcutaneous injection
postmarketing reports
renal failure
postmarketing reports: fibromas
postmarketing reports
reduced serum concentrations of thyroid hormones
postmarketing reports
peyronie
disease